Loading patent…
AssigneeNantOmics, LLC
InventorsDavid B. KRIZMAN, Todd HEMBROUGH, Eunkyung AN, Sheeno THYPARAMBIL, Wei-Li LIAO
Estimating the term…
The current disclosure provides methods for detecting and quantitating the 6-O-methylguanine-DNA methyltransferase protein (MGMT) directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring/Multiple Reaction Monitoring (SRM/MRM) mass spectrometry. Such biological samples are chemically preserved and fixed with formaldehyde containing agents/fixatives and may include formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and/or paraffin embedded. A protein sample is prepared from the biological sample and the MGMT protein is quantitated in the sample using SRM/MRM mass spectrometry by quantitating one or more fragment peptides.
-20. (canceled)
A method for measuring the level of the 6-O-methylguanine-DNA methyltransferase protein (MGMT) in a human biological sample of formalin-fixed tissue, comprising detecting and quantifying the amount of a MGMT fragment peptide in a protein digest prepared from said biological sample, using mass spectrometry, wherein said MGMT fragment peptide is the peptide having the sequence of SEQ ID NO:2 or SEQ ID NO:3;
The method of claim 1, further comprising selecting for the subject from which said biological sample was obtained a treatment based on the presence, absence, or amount of said MGMT fragment peptide or the level of MGMT protein.
Dependencies are inferred from the claim text.